Lawrence Corey
Affiliations: | University of Washington, Seattle, Seattle, WA |
Area:
Microbiology Biology, Molecular Biology, Cell BiologyGoogle:
"Lawrence Corey"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
McClymont E, Bone J, Orem J, et al. (2023) Increased frequency and quantity of mucosal and plasma cytomegalovirus replication among Ugandan Adults Living with HIV. Plos One. 18: e0287516 |
Gilbert PB, Huang Y, deCamp AC, et al. (2022) Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nature Medicine |
Byrne CM, Johnston C, Orem J, et al. (2021) Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads. Plos Computational Biology. 17: e1009072 |
Gray GE, Bekker LG, Laher F, et al. (2021) Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. The New England Journal of Medicine. 384: 1089-1100 |
Curlin ME, Shao J, Diaz G, et al. (2020) Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. Vaccine |
Schiffer JT, Johnston C, Wald A, et al. (2020) An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infectious Diseases. 7: ofaa232 |
DeRosa S, Edupuganti S, Huang Y, et al. (2020) Robust antibody and cellular responses induced by DNA-only vaccination for HIV. Jci Insight |
Cohen MS, Corey L. (2020) Combination prevention for COVID-19. Science (New York, N.Y.). 368: 551 |
Roychoudhury P, Swan DA, Duke ER, et al. (2020) Tissue-resident T cell derived cytokines eliminate herpes simplex virus-2 infected cells. The Journal of Clinical Investigation |
Laher F, Moodie Z, Cohen KW, et al. (2020) Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. Plos Medicine. 17: e1003038 |